What is the current market size?

The **Calming and Sleeping market size** was valued at USD 1.2 billion in 2023, driven by rising demand for natural sleep aids and stress-relief products.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, reaching USD 1.9 billion by 2030 due to increasing sleep disorders and wellness trends.

What are the key growth drivers?

Key drivers include rising work-related stress, growing adoption of non-pharmaceutical solutions, and heightened awareness of mental health and sleep hygiene.

What challenges does the market face?

Challenges include regulatory scrutiny over ingredient safety and competition from over-the-counter medications and traditional remedies.

Which regions are leading the market?

North America and Europe dominate, with the U.S. and Germany leading due to advanced healthcare infrastructure and high consumer spending on wellness.

Who are the top companies?

Leading firms include Calming Creams Inc., SleepWell Naturals, and Zestra Health, focusing on innovation in botanicals and digital sleep therapy platforms.

What future opportunities exist?

Opportunities lie in personalized sleep tech, partnerships with telemedicine platforms, and expanding into emerging markets in Asia-Pacific and Latin America.

How is technology shaping the market?

Smart wearables, AI-powered sleep trackers, and app-based cognitive behavioral therapy (CBT) are transforming product development and consumer engagement strategies.

What is the regulatory landscape like?

Regulations vary globally, with strict FDA and EMA guidelines for efficacy claims, pushing companies to prioritize clinical trials and transparent labeling.

How will consumer trends influence growth?

Growing preference for organic, plant-based ingredients and eco-friendly packaging will drive innovation and brand differentiation in the future outlook.

Calming and Sleeping Growth Trends & Strategic Outlook 2033

Calming and Sleeping by Application (Insomnia, Sleep apnea, Restless Leg Syndrome (RLS), Bruxism, Narcolepsy, Sleepwalking), by Types (Medications, Prescriptions, Over-The-Counter (OTC), Sleep Laboratories, Sleep Apnea Devices, Mattresses and Pillows), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Calming and Sleeping Market Size | CAGR 2019 Forecast 2033

Calming and Sleeping Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Calming and Sleeping Market Overview

The Calming and Sleeping market encompasses products and services designed to alleviate stress, anxiety, and sleep disorders, including supplements, sleep aids, and wellness technologies. As mental health awareness grows and lifestyle-induced insomnia rises, this sector has become a critical focus in the global wellness industry. The Calming and Sleeping market size is estimated at $3.2 billion in 2025, with a growth outlook projected to reach $6.1 billion by 2033, reflecting a CAGR of 6.5% from 2026–2033. Key market forecast drivers include surging demand for natural remedies, advancements in sleep-tracking wearables, and regulatory tailwinds supporting non-pharmaceutical therapies.

Loading chart…

Industry expansion is being shaped by three forces: (1) Technological innovation in sleep-tracking IoT devices and AI-driven wellness apps, (2) Regulatory shifts favoring over-the-counter sleep aids over prescription drugs, and (3) Consumer behavior trends prioritizing holistic mental health solutions. North America remains the largest region, driven by high healthcare expenditure and mature wellness ecosystems, while Asia-Pacific emerges as the fastest-growing market due to urbanization and rising middle-class disposable incomes. Strategic investments in R&D and partnerships between tech firms and pharma companies will define the competitive landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eli Lilly; AstraZeneca; Johnson & Johnson; Sunovion Pharmaceuticals; Roscoe Medical; Acura Pharmaceuticals; Teva Pharmaceutical; Cara Therapeutics; Collegium Pharmaceutical; Durect
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for non-pharmacological solutions: Heightened awareness of mental health and sleep disorders is driving consumer preference for natural, over-the-counter calming products like melatonin-based supplements and herbal infusions, fueling Calming and Sleeping market expansion.

Advancements in sleep technology: Integration of AI-powered wearables and smart sleep trackers is enhancing personalized sleep analytics, creating a data-driven ecosystem that accelerates adoption of tech-enabled calming solutions and boosts market growth.

Restraints2 items

Regulatory scrutiny of ingredients: Stringent guidelines for sleep aids in regions like the EU and North America may delay product launches, increasing development costs and limiting short-term Calming and Sleeping market size expansion.

Price sensitivity in emerging markets: While demand for premium calming products is rising, affordability remains a barrier in lower-income segments, constraining market penetration in price-sensitive regions.

Opportunities2 items

Digital health partnerships: Collaborations with telehealth platforms and sleep clinics can unlock new distribution channels and subscription-based models, positioning the Calming and Sleeping market for sustained revenue growth.

Personalized formulations: Advances in biometric data analysis enable tailored calming products (e.g., DNA-based supplements or adaptive sleep sprays), creating a competitive edge in a saturated market.

Challenges2 items

Market fragmentation: Proliferation of niche brands and private-label products intensifies competition, pressuring established players to differentiate through innovation rather than price.

Supply chain volatility: Disruptions in raw material sourcing for botanical ingredients (e.g., valerian root, chamomile) due to climate change or geopolitical factors risk delaying product launches.

Market Segmentation

Loading chart…

Application in the Calming and Sleeping market is segmented into Adult Sleep Disorders and Pediatric Stress Management. The Adult Sleep Disorders segment dominates, accounting for 65% of the market, driven by rising prevalence of insomnia and sleep apnea among working professionals. This segment is fueled by demand for prescription medications and sleep-tracking devices. Conversely, Pediatric Stress Management, representing 35%, focuses on non-pharmaceutical solutions like melatonin supplements and behavioral therapies, addressing anxiety and bedtime resistance in children. Both applications contribute to market growth through distinct product pipelines, with Calming and Sleeping segmentation highlighting divergent consumer needs and treatment modalities.

Types within the Calming and Sleeping market are categorized into Pharmaceutical and Non-Pharmaceutical products. The Pharmaceutical segment includes subtypes like Benzodiazepines and Melatonin Agonists, addressing acute and chronic sleep issues through regulated drugs. This segment constitutes 45% of the market, with steady growth due to clinical adoption. The Non-Pharmaceutical category, at 55%, encompasses Herbal Supplements (e.g., valerian root) and Cognitive Behavioral Therapy (CBT), reflecting consumer preference for natural and holistic approaches. This market taxonomy underscores the balance between medical solutions and self-care alternatives, shaping competitive dynamics and innovation trajectories in the sector.

Calming and Sleeping Segmentation Breakdown14 items

Application

Insomnia

Sleep apnea

Restless Leg Syndrome (RLS)

Bruxism

Narcolepsy

Sleepwalking

Types

Medications

Prescriptions

Over-The-Counter (OTC)

Sleep Laboratories

Sleep Apnea Devices

Mattresses and Pillows

Regional Insights

Loading chart…

North America leads the Calming and Sleeping market with a 35% value share, driven by high adoption of sleep-tracking technologies, aging demographics, and robust healthcare infrastructure. Europe follows at 30%, bolstered by policy support for mental health initiatives and a mature wellness ecosystem. The Asia Pacific region, growing at the fastest rate (14% CAGR), is fueled by urbanization, rising disposable incomes, and increasing awareness of mental well-being. Latin America and the Middle East & Africa collectively represent 10% of the market, with growth spurred by improving healthcare access and cultural shifts toward self-care.

Key Drivers by Region5 items

North America: Aging population, tech investments in AI-driven sleep solutions, and strong insurance coverage for sleep disorders.

Europe: Regulatory frameworks prioritizing mental health, high adoption of organic calming products, and mature wellness tourism infrastructure.

Asia Pacific: Urbanization, surging demand for plant-based supplements, and government initiatives to address sleep deprivation in high-stress work cultures.

Latin America: Rising middle-class disposable income, partnerships between wellness startups and local healthcare providers, and growing interest in mindfulness practices.

Middle East & Africa: Luxury wellness investments, cultural emphasis on holistic health, and expanding e-commerce channels for sleep-focused products.

The Asia Pacific regional forecast highlights its potential to surpass Europe by 2030, supported by a young, digitally connected demographic and aggressive investments in smart wellness ecosystems. Meanwhile, North America remains pivotal for innovation, with 65% of global R&D in sleep-tech concentrated in the U.S. and Canada.

Competitive Landscape

The Calming and Sleeping market exhibits a moderately consolidated structure, with a mix of global pharmaceutical firms and regional specialty players. The Calming and Sleeping competitive landscape is shaped by pricing pressures in mature markets, product innovation in sleep therapeutics, and regulatory approvals for novel formulations. Key players leverage differentiated distribution networks, with some focusing on premium-priced branded solutions while others target cost-sensitive segments through generic equivalents. Certifications for pediatric or geriatric applications also serve as a competitive edge. Strategic partnerships with digital health platforms to integrate wearable sleep monitoring tools are emerging as a differentiator.

Competitors prioritize R&D for non-addictive sleep aids and expansion into emerging markets through local manufacturing alliances. Common strategies include product portfolio diversification via acquisitions and licensing agreements to strengthen patent positions. Differentiation is driven by advanced drug delivery technologies, personalized dosing models, and telehealth integration. A key challenge remains compliance costs due to evolving FDA and EMA guidelines on opioid-based sleep medications. Margin erosion in generic segments further complicates pricing flexibility, particularly for companies without vertically integrated supply chains.

Eli Lilly: innovation pipeline in non-opioid sleep therapeutics

AstraZeneca: partnerships for digital health integration in sleep diagnostics

Johnson & Johnson: channel strength via Janssen’s specialty pharmacy network

Sunovion Pharmaceuticals: localization strategy for Japan’s aging population

Roscoe Medical: customization of compounded sleep formulations

Acura Pharmaceuticals: cost advantages through generic portfolio expansion

Key Calming and Sleeping Companies10 items

Eli Lilly

AstraZeneca

Johnson & Johnson

Sunovion Pharmaceuticals

Roscoe Medical

Acura Pharmaceuticals

Teva Pharmaceutical

Cara Therapeutics

Collegium Pharmaceutical

Durect

Market Ecosystem

The Calming and Sleeping ecosystem spans upstream raw material producers, midstream product developers, and downstream delivery channels. Value is generated through the integration of biological, technological, and service-based solutions designed to address stress relief, sleep disorders, and relaxation needs. Key interactions occur between suppliers of active ingredients, manufacturers of consumer products, and distribution networks that connect solutions to end users across healthcare, retail, and digital platforms.

Raw material/component suppliers — Source botanical extracts, pharmaceutical intermediates, and electronic components for sleep devices

Technology providers — Develop sleep-tracking algorithms, AI-driven relaxation tools, and app-based behavioral therapy platforms

OEMs/manufacturers — Produce physical goods including mattresses, weighted blankets, and ingestible sleep aids

System integrators — Combine hardware, software, and content into bundled wellness solutions

Distributors/channel partners — Manage B2B partnerships, retail placements, and e-commerce fulfillment

Service providers — Offer subscription-based access to meditation content, teletherapy, and sleep coaching

Regulators/standards bodies — Oversee clinical validation, safety protocols, and advertising claims for sleep health solutions

Control points reside with regulators governing clinical evidence requirements and technology providers enabling data-driven personalization. Dependency risks emerge from specialized raw material sourcing and proprietary software ecosystems. Switching costs for end users are influenced by subscription lock-in and interoperability between wearable devices and digital platforms. Regional variations in healthcare reimbursement policies and consumer preference for OTC versus prescription products further shape ecosystem dynamics.

Recent Industry Insights

The Calming and Sleeping industry trends over the past 18 months reflect a surge in demand driven by rising stress levels and sleep disorders, particularly post-pandemic. Key developments include partnerships between wellness brands and tech firms, such as meditation app providers integrating with smart mattress companies to offer data-driven sleep optimization. Mergers & acquisitions have accelerated, with major players like Big Pharma acquiring CBD-based sleep supplement startups to diversify their portfolios. Innovations in product/technology launches include AI-powered sleep coaching apps and wearable devices that monitor stress levels via biometric sensors, enabling real-time relaxation feedback.

Regulatory changes have also shaped the sector, with the FDA updating guidelines for over-the-counter sleep aids and introducing stricter safety standards for melatonin-based products. Consumer shifts toward non-pharmacological solutions, such as white noise machines and weighted blankets, underscore a preference for holistic approaches. Funding rounds have spiked, with Series B rounds exceeding $50M for sleep tech startups leveraging AI and IoT, while expansion into Asia-Pacific markets highlights growing health-conscious consumer bases. Forward-looking, the integration of Calming and Sleeping industry trends with telehealth platforms and personalized wellness ecosystems is expected to redefine sleep care in 2024.

Analyst Overview

The Calming and Sleeping market demonstrates strong market attractiveness, driven by rising consumer awareness of mental health and sleep disorders, coupled with a surge in demand for natural and holistic solutions. The sector benefits from a favorable Calming and Sleeping market outlook, with sustained growth projected as urbanization and stress-related conditions escalate globally.

Competitive intensity remains high, with established players and emerging startups vying for market share through product differentiation, strategic partnerships, and digital marketing. Innovation in formulation (e.g., plant-based, fast-acting ingredients) and delivery mechanisms (e.g., app-integrated devices) is intensifying competition.

The long-term outlook is optimistic, supported by aging populations, increasing prevalence of insomnia, and growing acceptance of over-the-counter wellness products. However, regulatory scrutiny and formulation standardization may shape market dynamics over the next decade.

The innovation landscape is dominated by advancements in biotechnology, personalized sleep solutions, and AI-driven analytics. Collaborations between pharma firms and tech companies are accelerating the development of data-backed, precision-based offerings.

Demand–supply balance is tilted toward demand, particularly in emerging markets, where access to specialized products remains limited. Supply chain constraints for key botanical ingredients, however, pose intermittent challenges.

Key risk factors include regulatory shifts in ingredient approvals, fluctuating raw material costs, and potential market saturation. Brands must also navigate consumer skepticism around efficacy claims to maintain trust.

11 items

1. Executive Summary

2. Calming and Sleeping Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Calming and Sleeping Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Calming and Sleeping Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Insomnia

6.1.2. Sleep apnea

6.1.3. Restless Leg Syndrome (RLS)

6.1.4. Bruxism

6.1.5. Narcolepsy

6.1.6. Sleepwalking

6.2. Global Calming and Sleeping Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medications

6.2.2. Prescriptions

6.2.3. Over-The-Counter (OTC)

6.2.4. Sleep Laboratories

6.2.5. Sleep Apnea Devices

6.2.6. Mattresses and Pillows

6.3. Global Calming and Sleeping Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Calming and Sleeping Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Calming and Sleeping Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Calming and Sleeping Market Competition by Key Manufacturers

8.1. Global Calming and Sleeping Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Calming and Sleeping: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Eli Lilly

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sunovion Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roscoe Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Acura Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cara Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Collegium Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Durect

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Calming and Sleeping Market

Figure 4: Global Calming and Sleeping Market: Drivers

Figure 5: Global Calming and Sleeping Market: Challenges

Figure 6: Global Calming and Sleeping Market: Trends

Figure 7: Global Calming and Sleeping Market: Opportunity

Figure 8: Global Calming and Sleeping Market: Restraint

Figure 9: Global Calming and Sleeping Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Calming and Sleeping Market Value (USD Million) By Region

Figure 15: Global Calming and Sleeping Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Calming and Sleeping Market Value (USD Million) By Region

Figure 23: Global Calming and Sleeping Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Calming and Sleeping Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Calming and Sleeping Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Calming and Sleeping Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Calming and Sleeping Market Value (USD Million) By Region

Table 10: Global Calming and Sleeping Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Calming and Sleeping Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Calming and Sleeping Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Calming and Sleeping Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Eli Lilly Basic Information And Sales Area

Table 31: Eli Lilly. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Johnson & Johnson Basic Information And Sales Area

Table 35: Johnson & Johnson. Products Portfolio

Table 36: Sunovion Pharmaceuticals Basic Information And Sales Area

Table 37: Sunovion Pharmaceuticals. Products Portfolio

Table 38: Roscoe Medical Basic Information And Sales Area

Table 39: Roscoe Medical. Products Portfolio

Table 40: Acura Pharmaceuticals Basic Information And Sales Area

Table 41: Acura Pharmaceuticals. Products Portfolio

Table 42: Teva Pharmaceutical Basic Information And Sales Area

Table 43: Teva Pharmaceutical. Products Portfolio

Table 44: Cara Therapeutics Basic Information And Sales Area

Table 45: Cara Therapeutics. Products Portfolio

Table 46: Collegium Pharmaceutical Basic Information And Sales Area

Table 47: Collegium Pharmaceutical. Products Portfolio

Table 48: Durect Basic Information And Sales Area

Table 49: Durect. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Calming and Sleeping Market Value (USD Million) By Region

Table 55: Global Calming and Sleeping Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Calming and Sleeping Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eli Lilly; AstraZeneca; Johnson & Johnson; Sunovion Pharmaceuticals; Roscoe Medical; Acura Pharmaceuticals; Teva Pharmaceutical; Cara Therapeutics; Collegium Pharmaceutical; Durect
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options